Letter to the Editor: LIGHTSITE III: 13-Month Efficacy and Safety Evaluation of Multiwavelength Photobiomodulation in Nonexudative (Dry) Age-Related Macular Degeneration Using the LumiTheraTM Valeda Light Delivery System.

IF 2.3 2区医学 Q2 OPHTHALMOLOGY

Retina-The Journal of Retinal and Vitreous Diseases Pub Date : 2024-09-19 DOI:10.1097/IAE.0000000000004265

Nicolas Feltgen, Thomas Ach, Ulrich Bartz-Schmidt, Nikolaos Bechrakis, Nicole Eter, Lars Hattenbach, Heinrich Heimann, Hans Hoerauf, Albrecht Lommatzsch, Siegfried Priglinger, Andreas Stahl, Peter Walter, Armin Wolf, Focke Ziemssen, Salvatore Grisanti

引用次数: 0

查看原文本刊更多论文

致编辑的信LIGHTSITE III：使用 LumiTheraTM Valeda 光传输系统对非渗出性（干性）年龄相关性黄斑变性进行为期 13 个月的多波长光生物调节的疗效和安全性评估。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Retina-The Journal of Retinal and Vitreous Diseases 医学-眼科学

CiteScore

5.70

自引率

9.10%

发文量

554

审稿时长

3-6 weeks

期刊介绍： RETINA® focuses exclusively on the growing specialty of vitreoretinal disorders. The Journal provides current information on diagnostic and therapeutic techniques. Its highly specialized and informative, peer-reviewed articles are easily applicable to clinical practice. In addition to regular reports from clinical and basic science investigators, RETINA® publishes special features including periodic review articles on pertinent topics, special articles dealing with surgical and other therapeutic techniques, and abstract cards. Issues are abundantly illustrated in vivid full color. Published 12 times per year, RETINA® is truly a “must have” publication for anyone connected to this field.